Analyst firms · Barclays · MRK

Barclays MRK price target and rating history

Merck & Company Inc. (MRK) · Health Care

Barclays rates Merck & Company Inc. (MRK) Overweight with a $140 price target, as of its latest action on Feb 20, 2026. It has published 3 rating actions on MRK since October 2021, including 0 upgrades and 0 downgrades. Across 10 firms with a MRK price target in the last 12 months, the median target is $141.50. Barclays's $140 is 1% below that.

Current rating

Overweight

Price target

$140

Median target, all firms

$141.50

Actions on MRK

3

Barclays price target on MRK

Every Barclays rating on MRK

• Feb 20, 2026
  InitiateBarclays starts coverage at Overweight, price target $140
• Nov 1, 2021
  ReiterateBarclays raises its price target to $94 from $92, keeps Overweight
• Oct 8, 2021
  ReiterateBarclays raises its price target to $92 from $87, keeps Overweight

How other firms rate MRK

Each firm's latest rating and stated target in the last 12 months.

Questions about Barclays and MRK

What is Barclays's price target for MRK?

Barclays's latest stated price target for Merck & Company Inc. (MRK) is $140, from its action on Feb 20, 2026.

What is Barclays's rating on MRK?

Barclays rates MRK Overweight, a bullish rating, as of Feb 20, 2026.

When did Barclays last change its view on MRK?

On Feb 20, 2026, Barclays starts coverage at Overweight, price target $140.

How does Barclays's MRK target compare with other analysts?

Across 10 firms with a MRK price target in the last 12 months, the median target is $141.50. Barclays's $140 is 1% below that.

More MRK rating histories

• Morgan Stanley6
• Daiwa4
• Citigroup5
• Deutsche Bank3
• Wolfe Research3
• BMO Capital Markets4
• Wells Fargo3
• Berenberg3
• Leerink Partners5

All Barclays ratingsMRK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.